KIT V560_L576del

CI-VAR-00004555Explore in graph →CIViC 1550

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor3
KIT V560_L576del	Imatinib + PonatinibSubstitutes	Predictive	D	Supports Sensitivity Response	4	accepted	EID7393 In the patient-derived cell line GIST430 harboring KIT V560_L576del primary activating mutation implanted in mice, imatinib and ponatinib were shown to reduce KIT phosphorylation compared to the vehic… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT V560_L576del	Regorafenib Anhydrous	Predictive	D	Supports Sensitivity Response	2	accepted	EID4061 A GIST430 patient derived cell line expressing KIT V560_L576del primary activating mutation demonstrated insensitivity to regorafenib (IC50: 191nmol/L) treatment. IC50 was determined by assessing cell… (full text at CIViC) PMID 25239608 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.